These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 37224884)

  • 1. Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs.
    Thakral S; Yadav A; Singh V; Kumar M; Kumar P; Narang R; Sudhakar K; Verma A; Khalilullah H; Jaremko M; Emwas AH
    Ageing Res Rev; 2023 Jul; 88():101960. PubMed ID: 37224884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
    Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer's disease.
    Fronza MG; Alves D; Praticò D; Savegnago L
    Ageing Res Rev; 2023 Sep; 90():102033. PubMed ID: 37595640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.
    Dey A; Bhattacharya R; Mukherjee A; Pandey DK
    Biotechnol Adv; 2017; 35(2):178-216. PubMed ID: 28043897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentoxifylline as Add-On Treatment to Donepezil in Copper Sulphate-Induced Alzheimer's Disease-Like Neurodegeneration in Rats.
    Elseweidy MM; Mahrous M; Ali SI; Shaheen MA; Younis NN
    Neurotox Res; 2023 Dec; 41(6):546-558. PubMed ID: 37821782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease Therapeutic Approaches.
    Revi M
    Adv Exp Med Biol; 2020; 1195():105-116. PubMed ID: 32468465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ongoing journey of chalcone analogues as single and multi-target ligands in the field of Alzheimer's disease: A review with structural aspects.
    Sharma P; Singh M
    Life Sci; 2023 May; 320():121568. PubMed ID: 36925061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review on Alzheimer's disease pathophysiology and its management: an update.
    Kumar A; Singh A; Ekavali
    Pharmacol Rep; 2015 Apr; 67(2):195-203. PubMed ID: 25712639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the rationale for new treatment strategies in Alzheimer's disease?
    Rogawski MA
    CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.
    León R; Garcia AG; Marco-Contelles J
    Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism.
    Stern AL; Ghura S; Gannon PJ; Akay-Espinoza C; Phan JM; Yee AC; Vassar R; Gelman BB; Kolson DL; Jordan-Sciutto KL
    J Neurosci; 2018 May; 38(18):4288-4300. PubMed ID: 29632166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scope of β-Secretase (BACE1)-Targeted Therapy in Alzheimer's Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition.
    Das S; Sengupta S; Chakraborty S
    ACS Chem Neurosci; 2020 Nov; 11(21):3510-3522. PubMed ID: 33073981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbamate as a potential anti-Alzheimer's pharmacophore: A review.
    Singh YP; Kumar N; Chauhan BS; Garg P
    Drug Dev Res; 2023 Dec; 84(8):1624-1651. PubMed ID: 37694498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-dementia drugs for Alzheimer disease in present and future].
    Nabeshima T; Noda Y; Kamei H
    Nihon Yakurigaku Zasshi; 2002 Nov; 120(1):24P-29P. PubMed ID: 12491771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.